Investment Thesis
Whitehawk Therapeutics is a pharmaceutical company in severe financial distress with accelerating revenue collapse (-72.5% YoY to $7.1M) while burning $98M annually in free cash flow. With only $37.6M cash on hand, the company has less than 5 months of operational runway at current burn rates, making it at high risk of equity dilution or insolvency despite holding a balance sheet with minimal debt.
Strengths
- Zero long-term debt with clean balance sheet
- Excellent liquidity metrics (10.26x current and quick ratios)
- Stockholders' equity of $136.3M exceeds liabilities 9x
Risks
- Catastrophic cash burn of -$98M FCF with only $37.6M cash runway (4-5 months)
- Revenue collapsed 72.5% YoY indicating failed commercialization or pipeline failure
- Operating losses of -$114.4M on minimal $7.1M revenue suggests broken business model
- Biotech/pharma company with no meaningful revenue generation or path to profitability
- Will require significant capital raise or restructuring within months
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash balance (critical runway analysis)
- Revenue trend (any stabilization or further decline)
- Operating cash flow trajectory (indicates sustainability)
- Form 4 insider activity patterns (potential dilutive equity issuance signals)
Financial Metrics
Revenue
7.1M
Net Income
-20.6M
EPS (Diluted)
$-0.33
Free Cash Flow
-98.0M
Total Assets
150.8M
Cash
37.6M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-1,601.1%
Net Margin
-288.3%
ROE
-15.1%
ROA
-13.7%
FCF Margin
-1,371.4%
Balance Sheet & Liquidity
Current Ratio
10.26x
Quick Ratio
10.26x
Debt/Equity
0.00x
Debt/Assets
9.6%
Interest Coverage
-1,972.41x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-19T05:09:21.655219 |
Data as of: 2025-12-31 |
Powered by Claude AI